Obstetric and fetal/neonatal outcomes in pregnant women with frequent premature ventricular complexes and structurally normal heart

Int J Cardiol. 2023 Jan 15:371:160-166. doi: 10.1016/j.ijcard.2022.10.011. Epub 2022 Oct 8.

Abstract

Background: High premature ventricular complex (PVC) burden may increase the risk of left ventricular dysfunction and all-cause mortality. We aimed to evaluate maternal and neonatal outcomes of pregnant women with structurally normal heart having PVC burden ≥1%.

Methods: This retrospective cohort study used data from Chang Gung Research Database. Pregnancies from January 1, 2005, through June 30, 2020, with documented maternal PVC burden ≥1% by 24-h Holter monitor were identified. Pregnant women with a diagnosis of structural heart disease or arrhythmias other than PVC were excluded. We used propensity score matching (PSM) to balance the covariates between the PVC group and normal control group. The PVC group was classified into low-PVC (<10%) and high-PVC burden subgroups. The maternal and neonatal outcomes were assessed through 6 months after delivery or termination.

Results: After PSM, there were 214, 61, and 46 pregnant women enrolled in the normal control group, low-PVC burden, and high-PVC burden subgroups, respectively. The high-PVC and low-PVC burden subgroups had composite adverse maternal and neonatal events similar to the control group without use of antiarrhythmic drugs (AADs), but a higher proportion of placental abruption was observed in the high-PVC burden subgroup. Maternal age, diabetes, and overweight were significant predictors of composite adverse maternal events, whereas only maternal age was a significant predictor of composite adverse neonatal events.

Conclusions: High PVC burden was not associated with poor composite adverse maternal and neonatal outcomes with no need of AADs therapy in pregnant women with structurally normal heart.

Keywords: Fetal/neonatal outcomes; Maternal outcomes; Pregnancy; Premature ventricular complex; Structurally normal heart.

MeSH terms

  • Anti-Arrhythmia Agents / therapeutic use
  • Electrocardiography, Ambulatory / adverse effects
  • Female
  • Humans
  • Infant, Newborn
  • Placenta
  • Pregnancy
  • Retrospective Studies
  • Ventricular Dysfunction, Left*
  • Ventricular Premature Complexes* / complications
  • Ventricular Premature Complexes* / diagnosis
  • Ventricular Premature Complexes* / epidemiology

Substances

  • Anti-Arrhythmia Agents